Pfizer and BioNTech introduced Monday that they’re in search of emergency use authorization from the FDA for its Omicron-specific COVID-19 booster for youngsters ages 5-11.
The massive image: The businesses’ submission comes after Moderna on Friday requested emergency use authorization for its Omicron-specific COVID booster photographs for youngsters 6-17 years previous.
Driving the information: Pfizer and BioNTech additionally mentioned Monday that they’ve began a examine of various dosing regimens of the up to date boosters in kids 6 months to 11 years of age.
- The request is “supported by security and immunogenicity information,” the businesses mentioned in a information launch.
State of play: Vaccine uptake amongst older teams for the up to date booster, known as bivalent, has been sluggish. Roughly 4.4 million individuals have acquired up to date boosters to this point, which quantities to lower than 2% of these eligible, per the CDC.
- Nonetheless, that is possible an undercount as a consequence of reporting lags within the states.
- Anyone over 12 was eligible to obtain the Pfizer-BioNTech bivalent booster starting in August.
Go deeper… Specialists alarmed by COVID vaccination charges amongst America’s youngest youngsters